Immunotherapy Archives

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

lupus neovacs stellar limpet protein autoimmune immunotherapy biotech

News and Trends 21 Jan 2016

Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins

Neovacs in Paris (France) investigates immunotherapies for the treatment of autoimmune diseases and today signed a partnering agreement with the molluscan protein manufacturer, Stellar Biotechnologies (US). This joint venture will operate under the name of Neostell SAS, and it will be owned 30:70, the majority going to Neovacs. Neovacs is a biotech focused on an active immunotherapy technology platform (Kinoids) […]

January 21, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Jan 2016

Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam

This week we say ‘auf Wiedersehen’ to Germany and head West to the Netherlands and it’s capital city, Amsterdam. This city really does have it all, whether you’re looking for history, architecture or something more indulgent… it is also the location of our biotech of the week: Kiadis Pharma City: Amsterdam, Netherlands Founded: 1997 Employees: 23 (as of 12/2015) […]

January 15, 2016 - 2 minutesmins - By Philip Hemme

f star fcab immunoncology abbvie babraham cancer

News and Trends 13 Jan 2016

UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

This year has started with a rush of deals for many Biotechs. F-Star another such company, now signing up for an Immuno-Oncology deal with AbbVie using Bispecific Antibodies. Financial terms were not disclosed but in regards to the hype of the Immuno-Oncology field, it could be pretty high. F-Star is a Cambridge company based at the Babraham […]

January 13, 2016 - 2 minutesmins - By Philip Hemme

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

transgene pecvex oncolytic liver cancer lee pharma

News and Trends 11 Jan 2016

Transgene shares jump 50% in 2 days After Announcing Phase III Trial for Liver Cancer

This multinational Phase III Trial for an Oncolytic Immunotherapy for Advanced Liver Cancer could be what really defines French Transgene as the underdog which finally sprang to fame. Transgene, in Strasbourg, was founded in 1979, as France’s oldest Biotech (only 3 years after Genentech was born on the other side of the Atlantic). However, unlike Genentech, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

merck msd cancer immunoncology complix alphabody

News and Trends 7 Jan 2016

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

Complix is a Belgian Immuno-Oncology Biotech with a proprietary Alphabody platform, which has now attracted a €260M strategic drug discovery collaboration with Merck Sharp & Dohme (MSD). Under the terms of the agreement, Complix will use its proprietary Alphabody platform to tackle two intra-cellular cancer targets. One example is the myeloid leukemia cell-1 protein (MCL-1), […]

January 7, 2016 - 2 minutesmins - By Dani Bancroft

msd avelumab pdl1 immunooncology pfizer etinostat

News and Trends 5 Jan 2016

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms how PD-L1 receptor is seen as the current breakthrough therapeutic target in Immuno-Oncology. Program-Death ligand 1 (PD-L1) is already a common target for mAbs in immuno-oncology. If expressed on the tumor cells, this enables the […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

roche cellsqueeze sqz cell therapies Cancer

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins

Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam

UK Biotech starts 2016 by signing a (Massive?) Immuno-Oncology Deal with AbbVie

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Transgene shares jump 50% in 2 days After Announcing Phase III Trial for Liver Cancer

Alphabody Platform for Cancer Draws in €260M Discovery Deal with MSD

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!